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1. Introduction 
1.1 Treatment limitations of patients with breast cancer metastatic to the brain 
Although technical advances have resulted in marked improvement in the ability to 
diagnose and treat primary breast cancer, brain metastases constitute a common and 
increasing occurrence associated with considerable morbidity and mortality [Lin et al., 2008; 
Smedby et al., 2009]. The present standard treatment modalities including surgical resection, 
cranial irradiation and systemic chemotherapy each have serious adverse side effects and 
limits in efficacy. The few long-term survivors are inevitably left with cognitive deficits and 
other disabilities [Heimans & Taphoorn, 2002]. The existence of blood-brain and blood-
tumor barriers impedes drug delivery to the tumor. Finally the low therapeutic index 
between tumor sensitivity and toxicity to normal brain severely limits the ability to 
systemically deliver therapeutic doses of drugs or administer focal radiation therapy to the 
tumor. New treatment strategies are urgently needed. 
1.2 Transfer of genomic DNA from one cell type to another alters both the genotype 
and the phenotype of cells that take up the exogenous DNA 
Classic studies indicate that transfection of genomic DNA from one cell type to another 
results in integration of the transferred DNA and stable alteration of the genotype of the 
recipient cells. The transferred genes are replicated as the cells divide and are expressed. In 
one study the genome of adenine phosphoribosyltransferase-deficient mouse cells was 
modified to express the missing enzyme by transfer of DNA from mouse cells whose 
genome included the gene for the missing enzyme [Wigler et al., 1979]. Analogous findings 
were observed for membrane-associated determinants. In another study genomic DNA from 
human cells was transferred into polio virus-receptor-negative mouse cells and the 
transfected cells expressed the missing receptor [Mendersohn et al., 1986]. Others 
[Barraclough et al., 1998; Chen et al., 1997] used this approach to identify genes involved in 
metastasis. Another approach involved the generation of stable transfectants of mouse 
fibroblasts [Hsu et al., 1984; Kavathas & Herzenberg, 1983]. The transfected cells expressed 
human membrane T cell antigens, HLA determinants, and B2-microglobulin. The expression 
of the transferred human genes by the transfected cells was stable and long-term (more than 
six months). The proportion of the transfected mouse cells that expressed the human gene of 
interest was surprisingly large--in the range of 1/500. The importance of these findings for 
development of DNA-based tumor vaccines is that the transfer of genomic DNA into cells 
resulted in the expression of genes specifying missing enzymes, genes controlling cell 
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proliferation and metastasis, and genes specifying membrane associated determinants. An 
analogous approach can be used to prepare a vaccine for use in patients with malignant 
gliomas. Genes specifying tumor associated antigens (TAAs) that fail to provoke anti-tumor 
immunity can become highly immunogenic antigenic determinants if they are expressed by 
highly immunogenic cells.  
1.3 Multiple mutant/dysregulated genes in cancer cells specify TAAs 
A major rationale for the use of DNA-transfer to prepare vaccines for use in cancer therapy 
is that the vaccine expresses an array of multiple altered genes which define the malignant 
phenotype. Genetic instability in cancer cells is responsible for the formation of TAAs. TAAs 
such as ǃ- catenin [Robbins et al., 1996], gp100, Melan A/Mart-1 and tyrosinase in 
melanoma [de Vries et al., 1997] are differentiation antigens whose expression is 
dysregulated in cancer cells. Mutant genes also specify TAAs [van der Bruggen et al., 1991]. 
For example Boon found that a point mutation in a gene in P815 murine mastocytoma cells 
specified a tumor-rejection antigen [Boon et al., 1994]. Thus, the malignant cell-population is 
characterized by the presence of numerous TAAs, some of which are unique and others are 
differentially expressed by cancer cells but all are strong potential targets of immune-
mediated attack. 
1.4 DNA from the patient’s neoplasm is the ideal source of tumor antigens for 
immunotherapy  
Since the total number of different TAAs within the population of malignant cells is large 
and diverse, successful therapy will depend upon the use of a vaccine that is capable of 
inducing immunity to the broad array of tumor antigens that characterizes the patient’s 
cancer. Therapy based on the induction of immunity to a single antigen, or peptide, is less 
likely to be successful. Multi-epitope vaccines are expected to be more efficacious than 
single-epitope vaccines [Stevenson et al., 2004]. This is especially the case for malignant 
astrocytomas, where clinically relevant TAAs, i.e., immunity to TAAs that leads to tumor 
rejection, have not been identified. 
1.5 Characteristics of the modified cell line used as the recipient of tumor DNA 
Among other advantages of this approach, the cells chosen as DNA-recipients can be 
selected for their ability to enhance the immune response. The expression of both syngeneic 
and allogeneic MHC-determinants by the DNA recipient cells is important in order to obtain 
an optimum anti-tumor response [deZoeten et al., 2002]. The syngeneic determinants 
provide a restriction element for direct presentation of TAAs to CTLs of the host. Allogeneic 
antigens served as potent immune adjuvants. Numerous investigators found that the 
immunogenic properties of cancer cells could be enhanced if the cells were modified to 
express allogeneic MHC-determinants [Fearon et al., 1988; Gattoni-Celli et al., 1988; 
Hammerling et al., 1986; Hui et al., 1989; Nabel et al., 1996; Ostrand-Rosenberg et al., 1990]. 
The modified cells, which ordinarily proliferate in syngeneic immunocompetent recipients, 
were recognized as “foreign” and were rejected. In the mouse, immunization with tumor 
cells altered by the introduction and expression of allogeneic class I genes led to immune-
mediated rejection of the malignant cells and the induction of protective anti-tumor 
immunity. However, the introduction of genes specifying allogeneic determinants into cells 
from a primary neoplasm is technically challenging and not always successful. In contrast, 
transfer of DNA from the tumor into highly immunogenic syngeneic/allogeneic cells is 
consistently and reliably achieved. 
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1.6 Important advantages of preparing a vaccine by transfer of DNA from the patient’s 
neoplasm into nonmalignant fibroblasts  
A vaccine prepared by transfer of DNA from the patient’s neoplasm into highly 
immunogenic, nonmalignant human fibroblasts has a number of important advantages. A 
major advantage is that the cells used as recipients of the DNA can be selected for special 
properties, which will enhance the anti-tumor immune response. Since the recipient cells are 
capable of prolonged proliferation in vitro, and the transferred DNA is replicated as the cells 
divide, only a small quantity of DNA from the neoplasm is required to generate the vaccine. 
In addition, the number of transfected fibroblasts can be expanded as needed to obtain 
sufficient quantities for repeated immunizations of the cancer patient. The fibroblasts used 
as DNA-recipients will also express allogeneic class I determinants which is a desirable 
feature since this leads to an augmented immune response. In addition a cell line derived 
from the patient’s primary neoplasm does not have to be established, which is the case if 
genes specifying cytokines, allogeneic MHC-determinants, co-stimulatory molecules or 
other immune-augmenting properties are to be introduced into the autologous tumor cells. 
The establishment of tumor cell lines, especially cell lines derived from astrocytomas, is 
technically difficult, often not feasible and may not be representative of the tumor cell 
population as a whole. Furthermore hybrid cell vaccines prepared by fusion of tumor cells 
with antigen presenting cells pose similar concerns [Gong et al., 1997; Liang & Cohen, 1976, 
1977]. Immunization with tumor cells modified to secrete immune-augmenting cytokines 
such as IL-2 and GM-CSF has been investigated and shown to result in the development of 
generalized MHC-restricted anti-tumor immune responses in animal models. However 
tumor cells are also a source of immunosuppressive factors, which inhibit the anti-tumor 
activity of the effector cells [Strand & Galle, 1998; Whiteside & Rabinwich, 1998]. The DNA-
based vaccines are successful because a full complement of genes is transferred to the 
recipient cells which results in a robust signal for the development of anti-tumor immune 
responses. 
1.7 Advantages of DNA-based vaccines relative to other types of vaccines 
A number of different vaccination strategies are currently being evaluated [Ashley et al., 
1997; Condon et al., 1996; Gilboa et al., 1998; Nair et al., 1998; Nestle et al., 1998; Tighe et al., 
1998]. The approaches to vaccination with TAAs include those based on: a) defined antigens 
or antigenic peptides, b) tumor cell lysates or lysate fractions, and c) whole irradiated tumor 
cells or apoptotic tumor cell bodies. Clinical trials involving vaccines prepared using TAAs 
or TAA-derived epitopes presented by APCs or fed to dendritic cells (DCs) have shown 
some promising results. However, defined antigens have to be identified and purified, a 
tremendous effort requiring an “antigen discovery” approach. The quantity of purified 
antigen must be increased, to enable multiple immunizations of the cancer patient. While 
new TAAs are being discovered, the question of which TAA to be used in the vaccine is 
uncertain and extensively debated. The heterogeneity of antigen expression in the tumor cell 
population is likely to be a concern. Some tumor cells may not express the antigen chosen 
for therapy. In one study for example, it was found that expression of known tumor 
antigens such as gp100 and tyrosinase was variable in different melanoma lesions in the 
same patient [de Vries et al., 1997]. Not all the malignant cells in the patient’s neoplasm 
expressed these determinants. Since the tumor cell population is heterogeneous, tumor cells 
that fail to express the defined antigen chosen for therapy are likely to escape destruction by 
the activated immune system.  
www.intechopen.com
 
Brain Tumors - Current and Emerging Therapeutic Strategies 
 
392 
The major advantage of vaccines prepared by transfer of tumor DNA into nonmalignant 
fibroblasts is that TAAs do not have to be purified or produced in large quantities. In 
comparison with protein vaccines, DNA-based vaccines provide prolonged expression and 
direct presentation of tumor antigens which results in robust and long-lasting activation of 
the immune system. From a practical point of view, these vaccines are easy and relatively 
inexpensive to prepare. Unlike other strategies, vaccines can be prepared from only a 
limited quantity of tumor-derived DNA, which can be obtained from small surgical 
specimens (vaccines can routinely be prepared from 50 μg of DNA). Furthermore, the 
recipient fibroblasts can be selected to meet the requirement for rapid expansion in culture 
and MHC restriction. The DNA-based vaccines offer a number of important advantages, 
which greatly encourage their further development for cancer immunotherapy. 
1.8 Disadvantages of transfer of tumor-derived DNA transfer into fibroblasts for 
expression of TAAs  
While vaccination based on transfer of tumor-derived DNA into highly immunogenic cells 
has a number of advantages, there are concerns as well. Since the proportion of total DNA 
that specifies TAAs is likely to be small, it is possible that a large number of the transfected 
cells may not express TAAs or may express TAAs at low levels. This concern is minimized, 
however, by preclinical data which indicate that the proportion of the cells that take-up 
tumor DNA and express TAAs is sufficient to induce an effective anti-tumor immune 
response and to significantly increase survival [Lichtor et al., 2008]. Another concern related 
to therapy with DNA-based vaccines is that genes specifying normal ”self” antigens are 
likely to be expressed by the DNA-transfected cells, creating a danger that autoimmune 
disease might develop, although this has not been observed thus far. Inbred mice 
immunized with the DNA-based vaccine or tumor-bearing mice injected with therapeutic 
DNA-based vaccines failed to exhibit adverse effects [Lichtor et al., 2006]. Of course, 
protocols that depend upon the use of tumor cell-extracts, peptide eluates of tumor cells, 
fusion cells, cDNAs or RNAs derived from tumor cells are subject to the same concern. In 
DNA-based vaccines, genes encoding determinants expressed by non-neoplastic cells are 
likely to be present in the largest proportion relative to genes specifying TAAs. While the 
use of purified tumor antigen in the form of cDNA or polynucleotide vaccines specific for 
known TAAs eliminates this concern, those types of vaccines are dependent on the selection 
of the most “relevant” vaccinating epitope, as discussed above. It is also conceivable that a 
cellular vaccine, including one using nonmalignant fibroblasts might grow in the patient, 
forming a tumor. Conceivably, a transforming oncogene or a defective tumor suppressor 
gene might be transferred to a normal cell, provoking a neoplasm although this has not been 
observed. Overall, the disadvantages of DNA-based vaccines are few and are certainly no 
more difficult to overcome than those associated with other types of experimental tumor-
vaccines. 
1.9 Defects in TAA presentation by tumor cells  
Defects in presentation of TAAs by tumor cells have been described in both murine as well 
as human tumors [Ohlen et al., 1990; Restifo et al., 1991]. They can result in tumor cell 
“escape” from host immunity. One mechanism is the loss of MHC determinants, which 
results in the impaired ability of the tumors to present TAAs. Loss of MHC antigen 
expression in several murine tumors is correlated with an increase in the malignant 
properties of the cells [Cohen & Kim, 1994]. Melanomas that recurred in mice treated with a 
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vaccine prepared by transfer of DNA from murine melanoma cells into mouse fibroblasts 
were deficient in expression of MHC class I determinants [Kim & Cohen, 1994]. Primary and 
especially metastatic cells may have global or selective down-regulation of class I or class II 
HLA antigens, due to mutations in β2 microglobulin or TAP genes and thus they may fail to 
present TAAs in an immunogenic form to immune cells. Even if the host generates tumor-
specific CTLs, the effector cells may not be able to eliminate the tumor. In addition to a 
failure to express HLA antigens, tumors may not express co-stimulatory molecules resulting 
in an inadequate immune response to TAAs by the host. Immunization with a DNA-based 
vaccine can overcome certain of these tumor “escape” mechanisms. 
Significance  
The most compelling reason for the vaccination strategy involving DNA-based cellular 
vaccines is the current lack of effective therapy for patients with malignant brain tumors 
such as breast cancer metastatic to the brain. This is verified by the dismal survival statistics, 
which have remained essentially unchanged for 30 years. Immunization with a vaccine that 
induces strong anti-tumor responses is an attractive addition or possibly even an alternative 
to conventional therapies. The DNA-based vaccines described in this review have shown 
remarkable therapeutic efficiency and survival benefits in some initial murine preclinical 
studies.  
2. Experimental section 
2.1 Treatment of intracerebral breast cancer in C3H mice by immunization with 
syngeneic/allogeneic fibroblast transfected with DNA from breast cancer cells 
Whether results obtained by transfer of DNA from a tumor cell line into mouse fibroblasts 
can be applied to tumors that develop spontaneously is uncertain. Conclusions based on a 
model system involving tumor cell lines may not apply to neoplasms that arise 
spontaneously in patients. The appearance of spontaneous breast neoplasms in C3H mice 
provides an opportunity to investigate this question. DNA isolated from a breast neoplasm 
that arose spontaneously in the mammary gland of a C3H (H-2K) mouse in our animal 
colony (SB5b breast carcinoma cell line) was transferred into mouse fibroblasts (H-2k). To 
increase their immunogenic properties and to ensure rejection, the fibroblasts were modified 
to express H-2Kb determinants beforehand. H-2Kb determinants are allogeneic in C3H mice. 
The results indicated that C3H mice with intracerebral breast cancer treated solely by 
immunization with fibroblasts transfected with DNA from the same spontaneous breast 
neoplasm survived significantly longer (p<0.005) than mice in various control groups 
[Lichtor et al., 2005].  
2.2 T cell mediated toxicity toward intracerebral breast cancer in mice immunized with 
syngeneic/allogeneic transfected fibroblasts modified to secrete IL-2, GM-CSF or IL-
18 
An MTS cytotoxicity assay was used to detect the presence of T cells reactive with breast 
cancer cells in mice injected i.c. with the mixture of SB5b cells and the modified, DNA-
transfected fibroblasts. MTS is a tetrazolium compound which is bioreduced by viable cells 
into a formazan product that can be detected at 490 mm. The T cells obtained from the 
spleens of the injected mice were analyzed two weeks after the i.c. injection of the cell 
mixture. The results indicated that the cytotoxic response of greatest magnitude was in mice 
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injected i.c. with the mixture of SB5b cells and transfected fibroblasts modified to secrete IL-
2 or GM-CSF [Lichtor et al., 2005]. Lesser cytotoxic effects were present in mice injected i.c. 
with SB5b cells and transfected fibroblasts modified to secrete IL-18. 
2.3 The proportion of T cells responsive to tumor cells in mice bearing an 
intracerebral tumor immunized intracerebrally with syngeneic/allogeneic transfected 
fibroblasts modified to secrete IL-2, IL-18 or IL-2 + IL-18 
An ELISPOT-IFN-γ assay was used to determine the proportion of splenic T cells reactive 
with SB-5b cells in mice immunized with transfected fibroblasts modified to secrete IL-2, IL-
18 or both IL-2 and IL-18. The animals were injected i.c. with a mixture of 1.0 X 104 SB-5b 
breast carcinoma cells and 1.0 X 106 treatment cells consisting of LMKbIL-2/SB5b, LMKbIL-
18/SB5b, or a mixture of LMKbIL-2/SB5b and LMKbIL-18/SB5b cells. The animals were 
sacrificed at two weeks and an ELISPOT assay was done using the spleen cells to detect 
IFN-γ secretion in the presence of SB-5b tumor cells and antibodies against various T-cell 
subsets. The results indicate that the cellular anti-breast carcinoma immune response was 
mediated by CD4+, CD8+ and NK/LAK cells [Lichtor et al., 2005]. Although IL-18 secreting 
cells did not produce a significant anti-tumor immune response as detected with the 
ELISPOT assay, the combination of IL-2 with IL-18 secreting cells did result in an 
enhancement of the anti-tumor responses in comparison to animals that were treated with 
IL-2 secreting cells alone.  
2.4 Increased numbers of responding T-cells were detected in the spleens and 
cervical lymph nodes of naïve mice or mice with i.c. breast cancer injected into the 
brain with cells from the immuno
high
 pool 
An enrichment strategy for the vaccine was developed based on the hypothesis that if 
aliquots of a transfected cell population were divided into smaller populations, some 
populations by chance would contain more highly immunogenic cells than others. The 
populations with higher numbers of immunogenic cells could be identified by their stronger 
immunogenic response against SB5b cells in C3H/He mice. Two subpools that stimulated 
immunity to the greatest (immunohigh pool) and least (immunolow pool) extents after three 
rounds of enrichment were selected for further study. 
To determine if systemic anti-tumor immunity was generated in tumor-free mice injected i.c. 
with cells from the immunohigh pool, cervical lymph node and spleen cells from the injected 
mice were analyzed by ELISPOT IFN-γ assays for responding T cells. Naïve C3H/He mice 
received 2 i.c. injections at weekly intervals of 1.0 X 106 cells from the immunohigh pool. One 
week after the second injection, mononuclear cells from the spleens and cervical lymph 
nodes of the immunized mice were analyzed for the presence of T cells responsive to the 
breast cancer cells. As controls, an equivalent number of cells from the non-selected master 
pool or cells from the immunolow pool were substituted for cells from the immunohigh pool. 
As additional controls, the same protocol was followed except that the mice were injected 
i.c. with equivalent numbers of SB5b cells, with LMKb cells or with media. Mice injected 
with SB5b tumor cells received only one injection. The results from the cervical lymph nodes 
(figure 1) indicated that the highest number of responding cells was in mice injected i.c. with 
cells from the immunohigh pool (p < 0.005 vs. cells from mice in any of the other groups). 
Similar results were found in studies using the spleen cells from these animals [Lichtor et al., 
2008].  
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Fig. 1. Development of anti-tumor immunity in cervical lymph nodes from naïve mice 
injected intracerebrally with an enriched cellular vaccine. ELISPOT IFN-Ǆ assays for 
responding T cells in the cervical lymph nodes of mice injected i.c. with cells from the 
immunohigh pool. Naïve C3H/He mice received intracerebral injections through a small burr 
hole two times at weekly intervals with 1.0 X 106 cells from the immunohigh pool of 
transfected cells. One week after the second injection, mononuclear cells from the cervical 
lymph nodes of the injected mice were analyzed by ELISPOT IFN-Ǆ assays for responding T 
cells. As controls, cells from the non-enriched master pool (LMIL-2Kb/SB5b) or cells from 
the immunolow pool were substituted for cells from the immunohigh pool. As additional 
controls, the same protocol was followed except that the mice were injected i.c. with media 
or with equivalent numbers of either SB5b or LMKb cells, or the mice were not injected. The 
animals injected i.c. with SB5b cells alone were injected only once. In some instances, SB5b 
cells (stimulated) were added to the cervical lymph node cell suspensions 16 hrs before the 
ELISPOT IFN-Ǆ assays were performed (the ratio of spleen cells : SB5b cells = 10:1). In this 
assay the number of IFN-Ǆ spots/106 cervical lymph node cells is measured. Error bars 
represent one standard deviation. p < 0.005 for the difference in the number of spots in the 
group injected with high pool LMIL-2Kb/SB5b cells co-incubated with SB5b cells versus any 
of the other groups.  
ELISPOT IFN-γ assays were also used to determine the number of responding T cells in the 
spleens of mice with i.c. breast cancer injected into the tumor bed with cells from the 
immunohigh pool [Lichtor et al., 2008]. A micro cannula was placed into the right frontal lobe 
of C3H/He mice. SB5b cells (1.0 X 104 in 10 µl) were introduced into the brain through the 
cannula. On days two and nine following, the animals were injected through the cannula 
into the tumor bed with 1.0 X 106 cells from the immunohigh pool. As controls, the same 
procedure was followed except that the cells from the non-enriched master pool or cells 
from the immunolow pool were substituted for cells from the immunohigh pool. As additional 
controls, the tumor bearing mice were injected into the tumor bed with equivalent numbers 
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of non DNA-transfected LMKb cells or the mice were injected with SB5b cells alone. The 
results indicate that the highest number of responding T cells were in the spleens of tumor-
bearing mice injected i.c. with cells from the immunohigh pool (p < 0.05 versus the number of 
responding spleen cells in mice injected with cells from the master pool and p < 0.005 versus 
the number of spots obtained from any of the other groups). 
2.5 T-reg cells are relatively deficient in the spleens of mice with i.c. breast cancer 
injected into the tumor bed with cells from the immuno
high
 pool 
T-reg cells (regulatory T cells) are potent inhibitors of natural antitumor immunity. The 
success of immunotherapeutic protocols may depend upon the relative numbers of T-reg 
cells and cytotoxic T lymphocytes in tumor-bearing animals and patients. Quantitative RT-
PCR for Foxp3, a transcription factor characteristic of T-reg cells, was used to determine the 
relative proportions of T-reg cells in the spleens and brains of mice with i.c. breast cancer 
injected into the tumor bed with cells from the immunohigh pool of transfected cells. Naïve 
C3H/He mice were injected i.c. with 5.0 X 104 SB5b cells along with 1.0 X 106 cells from the 
immunohigh pool of transfected cells. One week later, the animals received a second i.c. 
injection of cells from the immunohigh pool through the same burr hole alone. As controls, 
the same procedure was followed except that the mice were injected with equivalent 
numbers of SB5b cells and cells from the non-enriched master pool or the immunolow pool. 
The results indicate that CD4+/CD25+/Foxp3+ T-reg cells were relatively deficient in the 
spleens but not in the brains of animals injected with cells from the immunohigh pool [Lichtor 
et al., 2008]. An analysis by FACS of the spleens of the injected animals revealed a relative 
deficiency of CD4+/CD25+ T cells and a corresponding increase in the relative numbers of 
CD8+ cells in the spleens of mice injected i.c. with cells from the immunohigh pool. 
3. Discussion 
Despite standard therapeutic approaches, the survival of patients with primary or metastatic 
tumors to the brain has not improved significantly in more than thirty years. There is an 
urgent need for new and more effective forms of treatment. Immunotherapy, designed to 
stimulate immunity to the autologous tumor, is under active investigation for a number of 
different histologic types of cancer. The enhanced immunotherapeutic properties of a 
vaccine prepared by transfer of a cDNA expression library derived from breast cancer cells 
into a mouse fibroblast cell line appears to have great potential in treatment of intracerebral 
tumors. As the transferred cDNA integrates spontaneously into the genome of the recipient 
cells, replicates as the cells divide and is expressed, the vaccine could be prepared from 
small amounts of tumor tissue, enabling treatment at an early stage of the disease, when 
tumor tissue is available in only limited amounts and the tumor is most susceptible to 
immune-based therapy. However, like other cellular tumor vaccines, only a small 
proportion of the transfected cell population was expected to have incorporated cDNA 
fragments that specified tumor antigens. A novel enrichment strategy has also been 
developed to increase the proportion of immunotherapeutic cells in the vaccine.  
A number of different strategies have been attempted to develop vaccines that generate 
enhanced anti-tumor immune responses in mice and patients with intracerebral neoplasms 
involving the central nervous system. Vaccines have been prepared by “feeding” antigen 
presenting (dendritic) cells apoptotic bodies from tumor cells or tumor cell lysates. 
Introduction of tumor cell-derived RNA into dendritic cells is another approach which has 
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been developed. Immunization with dendritic cells “fed” derivatives of tumor cells or 
transfected with tumor-RNA can result in the induction of immune responses against the 
broad array of tumor antigens expressed by the population of malignant cells including 
tumors of neuroectodermal origin [O et al, 2002; Rosenberg et al., 2004]. In patients, 
immunization with autologous dendritic cells transfected with mRNA from malignant 
glioma elicited tumor-specific CD8+ cytotoxic T-lymphocyte (CTL) responses against the 
patient’s malignant cells [Kobayashi et al., 2003]. Although results of dendritic cell 
immunotherapy have demonstrated promise in animal models, clinical trials have been 
disappointing thus far [Rosenberg et al., 2004].  
Other tumor vaccination strategies have been used including modification of neoplastic cells 
to generate anti-tumor immune responses [Colombo et al., 1991; Gansbacher et al., 1990; 
Golumbek et al., 1991; Mullen et al., 1992]. Immunization with tumor cells modified to 
secrete immune-augmenting cytokines such as IL-2 and GM-CSF has resulted in the 
development of generalized MHC-restricted anti-tumor immune responses in animal 
models [Cavallo et al., 1993; Connor et al., 1993; Dranoff et al., 1993; Marincola et al., 1994; 
Ohlen et al., 1990, Tahara et al., 1994]. Selective tumor regression was observed in 
experimental animals and patients receiving immunotherapy alone, in support of the 
potential of this type of treatment for patients with malignant disease [Valmori et al., 2000]. 
The effects of cytokine expression by central nervous system tumors (CNS) were examined 
initially using glioma cells that were engineered to secrete IL-4 [Yu et al., 1993]. In these 
studies it was demonstrated that IL-4 transduced glioma cells resulted in the development 
of anti-tumor immune responses. Delivery of an IFN-ǃ expression plasmid by cationic 
liposomes to the CNS tumor site was also found to induce significant anti-CNS tumor 
immunity in pre-clinical models [Liu et al., 2002]. Use of a high-titer adenoviral vector 
encoding IL-12 is another strategy that was reported to induce anti-tumor responses in a 
glioma model [Liu et al., 2002]. Epidermal growth factor variant III is a common alteration 
of the epidermal growth factor receptor found in human tumors, and a peptide vaccine has 
now proceeded to phase 1 and 2 clinical trials in patients bearing a malignant glioma with 
the ability of inducing potent T- and B-cell immunity and prolongation of survival 
[Sampson et al., 2008; Li et al., 2010].  
In addition to immunotherapy, other gene therapy strategies have been attempted in the 
treatment of brain tumors. For example genetically modified, conditionally-replicating 
Herpes Simplex Virus Type 1 vectors with anti-tumor activity have been used with some 
encouraging results in Phase I and Phase II clinical trials [Cassady & Parker, 2010]. RNA 
interference therapy has also been shown to exhibit some therapeutic effects in pre-clinical 
and clinical studies in patients with gliomas [Guo et al., 2010]. High grade gliomas have 
been shown to express an IL-13 receptor that differs from the natural lL-13 receptor, and 
some pre-clinical and clinical trials have been undertaken using an adenoviral vector 
encoding a mutated human IL-13 fused to pseudomonas exotoxin that specifically binds to 
the IL-13 receptor [Candolfi et al., 2010]. Antisense oligodeoxynucleotides which target 
mRNA encoding TGF-beta2, a cytokine secreted by brain tumors with immunosuppressive 
activity, have been used in a series of Phase I and II clinical trials along with an international 
Phase III study with some success [Hau et al., 2009]. Finally one of the problems using large 
viruses in treating brain tumors is that the viruses have a limited capacity to infiltrate into 
the brain, but recently it has been shown that neural stem cells infected with replicating 
adenovirus can be used to enhance intratumoral distribution of the oncolytic vectors into a 
malignant glioma in comparison with virus injection alone [Tyler et al., 2009].  
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Previous studies indicated that transfection of genomic DNA from the malignant cells into a 
fibroblast cell line resulted in stable integration and expression of the transferred DNA 
[Cohen, 2001; Lichtor et al., 2005; Lichtor et al., 2006; Lichtor et al., 2008]. Both the genotype 
and the phenotype of the cells that took up the exogenous DNA were altered as portions of 
the transferred DNA were expressed. Immunization of tumor-bearing mice with the DNA-
based vaccine resulted in the induction of cell mediated immunity directed toward the type 
of tumor from which the DNA was obtained, and prolongation of survival, consistent with 
the expression of an array of TAA by the transfected cells. This was the case for mice with 
melanoma, squamous cell carcinoma and in mice with breast cancer [Chopra et al., 2006; 
deZoeten et al., 2002; Lichtor et al., 2008]. Multiple undefined genes specifying TAA that 
characterize the malignant cell population were expressed by cells that took up DNA from 
the tumor. The number of vaccine cells could be expanded as required for multiple 
immunizations. In addition, the recipient cells can also be modified before DNA-transfer to 
increase their immunogenic properties, as for example, by the introduction of genes 
specifying immune-augmenting cytokines or allogeneic MHC-determinants, which act as 
strong immune adjuvants.  
4. Conclusions 
To be successful, every remaining tumor cell in the patient must be eliminated. It is unlikely 
that a single form of therapy is capable of achieving this goal. However immunotherapy in 
combination with surgery, radiation therapy and chemotherapy will likely find a place as a 
new and important means of treatment for patients with brain tumors. A major advantage 
of DNA-based vaccines is that they do not require protein purification or its production and 
yet they are able to elicit robust and long-lasting activation of the immune response, which 
results in tumor rejection. From a practical point of view, these vaccines are easy to prepare 
and they are relatively inexpensive. Only a limited quantity of tumor-derived DNA is 
required, which can be obtained from small surgical specimens. The enrichment strategy 
enables the generation of highly immunogenic pools of transfected cells with enhanced 
immunotherapeutic properties.  
Thus DNA-based vaccines offer a number of advantages, which greatly encourage their 
further development for cancer immunotherapy in general and specifically for treatment of 
breast cancer metastatic to the brain.  
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